Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond

Current Opinion in Lipidology

Volumn 10, Issue 3, 1999, Pages 207-217

  Mahley, Robert W ^a,b   Huang, Yadong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; LIPID; LIPOPROTEIN RECEPTOR; PROTEOHEPARAN SULFATE; VERY LOW DENSITY LIPOPROTEIN;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; GENETIC PREDISPOSITION; LIPID BLOOD LEVEL; LIPOLYSIS; LIPOPROTEIN METABOLISM; NEUROBIOLOGY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 0032839621     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199906000-00003     Document Type: Review

References (99)

1. 1 Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240:622-630.
2. 2 Mahley RW, Ji Z-S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999; 40:1-16. An extensive review on the role of apoE in receptor-mediated lipoprotein uptake.
3. 3 Weisgraber KH, Mahley RW. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 1996; 10:1485-1494.
4. 4 Shore VG, Shore B. Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components. Biochemistry 1973; 12:502-507.
5. 5 Mahley RW. Alterations in plasma lipoproteins induced by cholesterol feeding in animals including man. In: Disturbances in lipid and lipoprotein metabolism. Dietschy JM, Gotto AM, Jr., Ontko JA (editors). Bethesda: American Physiological Society; 1978: pp 181-197.
6. 6 Mahley RW. Development of accelerated atherosclerosis. Concepts derived from cell biology and animal model studies. Arch Pathol Lab Med 1983; 107: 393-399.
7. 7 Mahley RW. Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: The metabolic and molecular bases of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D (editors). New York: McGraw-Hill; 1995: pp 1953-1980.
8. 8 Innerarity TL, Mahley RW. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978; 17:1440-1447.
9. 9 Bersot TP, Mahley RW, Brown MS, Goldstein JL. Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts. J Biol Chem 1976; 251:2395-2398.
10. 10 Utermann G, Jaeschke M, Menzel J. Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEBS Lett 1975; 56:352-355.
11. 11 Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 1981; 20:1033-1041.
12. 12 Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994; 45: 249-302.
13. 13 Mahley RW. Apolipoprotein E: structure and function in lipid metabolism and neurobiology. In: The molecular and genetic basis of neurological disease. Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL (editors). Boston: Butterworth-Heinemann; 1997: pp 1037-1049.
14. 14 Mahley RW, Nathan BP, Bellosta S, Pitas RE. Apolipoprotein E: impact of cytoskeletal stability in neurons and the relationship to Alzheimer's disease. Curr Opin Lipidol 1995; 6:86-91.
15. 15 Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47:387-400.
16. 16 Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 1977; 269:604-607.
17. 17 Havel RJ, Kane JP. Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins. Proc Natl Acad Sci U S A 1973; 70:2015-2019.
18. 18 Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, et al. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest 1981; 68:1075-1085.
19. 19 Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982; 257:2518-2521.
20. 20 Rall SC Jr., Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982; 257:4171-4178.
21. 21 Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The metabolic and molecular bases of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D (editors). New York: McGraw-Hill; 1995: pp 1981-2030.
22. 22 Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981; 212:628-634.
23. 23 Sherrill BC, Innerarity TL, Mahley RW. Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. Identity with the chylomicron remnant transport process. J Biol Chem 1980; 255:1804-1807.
24. 24 Windler E, Chao Y-S, Havel RJ. Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem 1980; 255:5475-5480.
25. 25 Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988; 7:4119-4127.
26. 26 Herz J, Willnow TE. Functions of the LDL receptor gene family. Ann NY Acad Sci 1994; 737:14-19
27. 27 Brown MS, Herz J, Kowall RC, Goldstein JL. The low-density lipoprotein receptor-related protein: double agent or decoy? Curr Opin Lipidol 1991; 2:65-72.
28. 28 Herz J, Willnow TE. Lipoprotein and receptor interactions in vivo. Curr Opin Lipidol 1995; 6:97-103.
29. 28 Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci U S A 1989; 86:5810-5814.
30. 30 Ji Z-S, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 1993; 268:10160-10167.
31. 31 Ji Z-S, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem 1994; 269:13421-13428.
32. 32 Ji Z-S, Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res 1995; 36:583-592.
33. 33 Mahley RW, Weisgraber KH, Innerarity TL. Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim Biophys Acta 1979; 575:81-91.
34. 34 Ji Z-S, Fazio S, Lee Y-L, Mahley RW. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J Biol Chem 1994; 269:2764-2772.
35. 35 Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991; 88:8342-8346.
36. 2-macroglobulin receptor in vitro. A process facilitated by cell-surface proteoglycans. J Biol Chem 1993; 268:14168-14175.
37. 37 Ji Z-S, Lauer SJ, Fazio S, Bensadoun A, Taylor JM, Mahley RW. Enhanced binding and uptake of remnant lipoproteins by hepatic lipase-secreting hepatoma cells in culture. J Biol Chem 1994; 269:13429-13436.
38. 38 Ji Z-S, Dichek HL, Miranda RD, Mahley RW. Heparan sulfate proteoglycans participate in hepatic lipase-and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem 1997; 272:31285-31292.
39. 39 Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994; 264:1471-1474.
40. 2-macroglobulin receptor. J Biol Chem 1991; 266:13936-13940.
41. 41 Wetterau JR, Aggerbeck LP, Rall SC Jr., Weisgraber KH. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem 1988; 263:6240-6248.
42. 42 Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu C-SC, Lindgren FT. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino-and carboxyl-terminal domains. J Biol Chem 1988; 263:6249-6258.
43. 43 Dong L-M, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, et al. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem 1994; 269:22358-22365.
44. 44 Dong L-M, Weisgraber KH. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem 1996; 271:19053-19057.
45. 45 Inneraity TL, Weisgraber KH, Arnold KS, Rall SC Jr., Mahley RW. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. J Biol Chem 1984; 259:7261-7267.
46. 46 Bradley WA, Hwang S-LC, Karlin JB, Lin AHY, Prasad SC, Gotto AM Jr., et al. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. J Biol Chem 1984; 259:14728-14735.
47. 47 Weisgraber KH, Rall SC Jr., Mahley RW, Milne RW, Marcel YL, Sparrow JT. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem 1986; 261:2068-2076.
48. 48 Wilson C, Mau T, Weisgraber KH, Wardell MR, Mahley RW, Agard DA. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure 1994; 2:713-718.
49. 49 Lalazar A, Weisgraber KH, Rall SC Jr., Giladi H, Innerarity TL, Levanon AZ, et al. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem 1988; 263:3542-3545.
50. 50 Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991; 252:1817-1822.
51. 51 Salah D, Bohnet K, Gueguen R, Siest G, Visvikis S. Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein level in the Stanislas cohort. J Lipid Res 1997; 38:904-912.
52. 52 Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J Jr., et al. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1996; 16:149-159.
53. 53 Huang Y, Li XQ, Rall SC, Jr., Taylor JM, von Eckardstein A, Assmann G, et al. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem 1998; 273:26388-26393. A new role for apoE in causing hypertriglyceridemia by inhibiting lipolytic hydrolysis and stimulating VLDL production.
54. 54 Chait A, Hazzard WR, Albers JJ, Kushwaha RP, Brunzell JD. Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia. Metabolism 1978; 27:1055-1066.
55. 55 Ehnholm C, Mahley RW, Chappell DA, Weisgraber KH, Ludwig E, Witztum JL. Role of apolipoprotein E in the lipolytic conversion of β-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. Proc Natl Acad Sci U S A 1984; 81:5566-5570.
56. 56 Huang Y, Liu XQ, Rall SC, Jr., Mahley RW. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J Biol Chem 1998; 273:17483-17490. One of the important unanswered questions related to type III hyperlipoproteinemia is the cause of low LDL levels.
57. 57 Rensen PCN, van Berkel TJC. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J Biol Chem 1996; 271:14791-14799.
58. 58 Jong MC, Dahlmans VEH, Hofker MH, Havekes LM. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem J 1997; 328:745-750.
59. 59 Huang Y, Rall SC Jr., Mahley RW. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Arterioscler Thromb Vasc Biol 1997; 17:2817-2824.
60. 60 Huang Y, Schwendner SW, Rall SC Jr., Mahley RW. Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2. J Biol Chem 1996; 271:29146-29151.
61. 61 Utermann G. Genetic polymorphism of apolipoprotein E-impact on plasma lipoprotein metabolism. In: Diabetes, obesity and hyperlipidemias. Vol III. Crepaldi G, Tiengo A, Baggio G (editors). Amsterdam: Elsevier Science Publishers; 1985: pp 1-28.
62. 62 Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8:1-21.
63. 63 Woollett LA, Osono Y, Herz J, Dietschy JM. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc Natl Acad Sci USA 1995; 92:12500-12504.
64. 64 Fan J, Ji Z-S, Huang Y, de Silva H, Sanan D, Mahley RW, et al. Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma. J Clin Invest 1998; 101:2151-2164. Overexpression of human apoE3 in transgenic rabbits results in increased LDL levels secondary to impaired clearance because of competition for receptor binding in apoE3-enriched lipoproteins.
65. 65 Huang Y, Ji Z-S, Brecht WJ, Rall SC Jr., Taylor JM, Mahley RW. Over expression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic very low density lipoprotein (VLDL) production and impairing VLDL lipolysis. Arterioscler Thromb Vasc Biol 1999 (in press).
66. 66 Kuipers F, Jong MC, Lin Y, van Eck M, Havinga R, Bloks V, et al. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J Clin Invest 1997; 100:2915-2922. The authors demonstrate that the absence of apoE expression in the liver is associated with a 50% reduction in VLDL production.
67. 67 Weisgraber KH, Pitas RE, Mahley RW. Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E. Curr Opin Struct Biol 1994; 4:507-515.
68. 68 Elshourbagy NA, Liao WS, Mahley RW, Taylor JM. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci USA 1985; 82:203-207.
69. 69 Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 1987; 262:14352-14360.
70. 70 Ignatius MJ, Gebicke-Härter PJ, Skene JHP, Schilling JW, Weisgraber KH, Mahley RW, et al. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci USA 1986; 83:1125-1129.
71. 71 Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, et al. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 1989; 83:1015-1031.
72. 72 Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994; 264:850-852.
73. 73 Nathan BP, Chang K-C, Bellosta S, Brisch E, Ge N, Mahley RW, et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem 1995; 270:19791-19799.
74. 74 Bellosta S, Nathan BP, Orth M, Dong L-M, Mahley RW, Pitas RE. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem 1995; 270:27063-27071.
75. 75 Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 11:575-580.
76. 76 Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-923.
77. 77 Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7:180-184.
78. 78 Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD. Apolipoprotein E-e2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 1997; 48:515-519.
79. 79 Slooter AJC, Tang M-X, van Duijn CM, Stern Y, Ott A, Bell K, et al. Apolipoprotein E £4 and the risk of dementia with stroke. A population-based investigation. J Am Med Assoc 1997; 277:818-821.
80. 80 Nicoll JAR, Roberts GW, Graham DI. Amyloid β-protein, APOE genotype and head injury. Ann NY Acad Sci 1996; 777:271-275.
81. 81 Holtzman DM, Pitas RE, Kilbridge J, Nathan B, Mahley RW, Bu G, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci USA 1995; 92:9480-9484.
82. 82 Sun Y, Wu S, Bu G, Onifade MK, Patel SN, LaDu MJ, et al. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci 1998; 18:3261-3272.
83. 83 DeMattos RB, Curtiss LK, Williams DL. A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J Biol Chem 1998; 273:4206-4212.
84. 84 Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong L-M, Jakes R, et al. Isoforrn-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 1994; 91:11183-11186.
85. 85 Ji Z-S, Pitas RE, Mahley RW. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than E4. J Biol Chem 1998; 273:13452-13460. Evidence is provided for a greater accumulation of apoE3 than apoE4 in cells. The differential accumulation is mediated by uptake via cell surface HSPG.
86. 86 Han S-H, Einstein G, Weisgraber KH, Strittmatter WJ, Saunders AM, Pericak-Vance M, et al. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: A light and electron microscopic study. J Neuropathol Exp Neurol 1994; 53:535-544.
87. 87 Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991; 541:163-166.
88. 88 Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-M, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:8098-8102.
89. 89 Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, et al. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994; 94:860-869.
90. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994; 372:92-94.
91. 91 Wisniewski T, Castaño EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994; 145:1030-1035.
92. 92 LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 1994; 269:23403-23406.
93. 93 Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, et al. LDL receptor-related protein, a multifunctional apoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation. Cell 1995; 82:331-340.
94. 94 LaDu MJ, Lukens JR, Reardon CA, Getz GS. Association of human, rat, and rabbit apolipoprotein E with β-amyloid. J Neurosci Res 1997; 49:9-18.
95. -/- mice: isoform-specific effects on neurodegeneration. J Neurosci 1999 (in press).
96. 96 Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 1995; 136:107-122.
97. 97 Sheng H, Laskowitz DT, Bennett E, Schmechel DE, Bart RD, Saunders AM, et al. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab 1998; 18:361-366.
98. 98 Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci USA 1998; 95:10914-10919. ApoE4 expression in the brains of apoE-null mice is associated with impaired ability to perform a water maze task and decreased exploratory activity. ApoE3 expression is not associated with these deficiencies.
99. 99 Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342:697-699.